Sign Up Today and Learn More About Belharra Therapeutics Stock
Invest in or calculate the value of your shares in Belharra Therapeutics or other pre-IPO companies through EquityZen's platform.
Belharra Therapeutics Stock (BELT)
Belharra Therapeutics disrupts the drug discovery paradigm with its novel photoaffinity-based chemoproteomics platform.
About Belharra Therapeutics Stock
Founded
2021
Headquarters
San Diego, CA, US
Industries
Software, Artificial Intelligence, Data and Analytics
Belharra Therapeutics Press Mentions
Stay in the know about the latest news on Belharra Therapeutics
Belharra Therapeutics Announces Appointment of Sean Buchanan, Ph.D., as Chief Scientific Officer and Retirement of Gary O’Neill, Ph.D.
morningstar • Jan 11, 2025
Belharra Therapeutics sticks with lead programs, trims workforce by 40%
sdbn • Dec 10, 2024
Belharra Therapeutics on LinkedIn: #drugdiscovery #biotechpartnering #bigpharmapartnerships #chemoproteomics…
linkedin • Aug 03, 2024
Belharra Therapeutics Announces Strategic Collaboration with Sanofi to Advance Discovery of Novel Small Molecule ...
globenewswire • Jun 26, 2024
Sanofi to surf Belharra in $700M biobucks immunology deal
fiercebiotech • Jun 26, 2024
Belharra Therapeutics Management
Leadership team at Belharra Therapeutics
CEO
Jeff Jonker
Board Member
Tom Woiwode
Join now and verify your accreditation status to gain access to:
- Belharra Therapeutics Current Valuation
- Belharra Therapeutics Stock Price
- Belharra Therapeutics Management
- Available deals in Belharra Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Belharra Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Belharra Therapeutics Revenue and Financials
- Belharra Therapeutics Highlights
- Belharra Therapeutics Business Model
- Belharra Therapeutics Risk Factors
- Belharra Therapeutics Research Report from SACRA Research
Trading Belharra Therapeutics Stock
How to invest in Belharra Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Belharra Therapeutics through EquityZen funds. These investments are made available by existing Belharra Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Belharra Therapeutics stock?
Shareholders can sell their Belharra Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 350K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 45K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
